GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better ...

The tech company estimates that its investment will create 100,000 jobs focused on AI and emerging technologies. Canal+'s shares fell on the London Stock Exchange and Havas's stock rose on Euronext ...

Ratings for the No. 2 and No. 3 cable news networks have plummeted since Donald Trump's victory, while Fox News remains the leader. The president-elect sued after George Stephanopoulos inaccurately ...

The global obesity epidemic represents one of the most pressing public health challenges of our time. With nearly ...

Robert F. Kennedy Jr., a prominent critic of the pharmaceutical industry, discussed his views regarding GLP-1 weight loss drugs in a televised broadcast.

Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug ...

The Australian market is poised for a positive start with the ASX 200 expected to open slightly higher, buoyed by China's commitment to proactive fiscal policies which has positively impacted ...

In the first head-to-head test, Eli Lilly's Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk's Wegovy. People taking Zepbound lost 20.2% of ...

Eli Lilly and Company LLY announced that its popular obesity drug, Zepbound (tirzepatide) demonstrated more weight loss than rival Novo Nordisk’s NVO Wegovy in a first-ever head-to-head obesity ...

Eli Lilly (NYSE:LLY) has been making headlines recently with its weight-loss drug Zepbound (tirzepatide). Eli Lilly's weight-loss drug Zepbound (tirzepatide) just proven to be more effective than Novo ...

Those same investors will also know, however, that this company's biggest growth drivers at this time are the weight-loss drug Zepbound and the diabetes treatment Mounjaro. After 2022's approval ...

People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday.